Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00338962 · ClinicalTrials.gov registry record · Phase 3
Naltrexone & SSRI in Alcoholics With Depression/PTSD
A Phase 3 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 3
- Development phase
- 88
- Enrollment target
NCT00338962 is a Phase 3 study that has completed, run by Yale University. The registered enrollment target is 88 participants.
The verdict
NCT00338962, a Phase 3 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 88 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of naltrexone in combination with an SSRI to reduce alcohol consumption in alcoholic patients with comorbid PTSD and depression. We hypothesize that the combination of naltrexone and SSRI will exhibit a greater decrease in alcohol consumption than that seen with treatment with SSRI alone, or with a combination of another class of antidepressant and naltrexone. We also hypothesize that SSRI will be effective in treating PTSD and depressive symptoms and naltrexone will be well tolerated.
Interventions
- DRUG Placebo
- DRUG Naltrexone
- DRUG paroxetine
- DRUG desipramine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2001-10 |
| Est. Completion | 2015-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00338962
The ClinicalTrials.gov registry entry for NCT00338962 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00338962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00338962 about?
NCT00338962 is a clinical study titled "Naltrexone & SSRI in Alcoholics With Depression/PTSD". The purpose of this study is to evaluate the efficacy of naltrexone in combination with an SSRI to reduce alcohol consumption in alcoholic patients with comorbid PTSD and depression. We hypothesize that the combination of naltrexone and SSRI will exhibit a greater decrease in alcohol consumption th...
What is the current status of trial NCT00338962?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 88 participants. The study started on 2001-10. Estimated completion is 2015-07.
What interventions are being tested in trial NCT00338962?
The interventions under investigation include: Placebo (DRUG), Naltrexone (DRUG), paroxetine (DRUG), desipramine (DRUG).
Who is sponsoring clinical trial NCT00338962?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.